The Medical Letter on Drugs and Therapeutics
Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a subcutaneous (SC) extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Sublocade – Indivior) for once-monthly treatment of moderate to severe opioid use disorder.1 Sublocade is the first injectable buprenorphine product to be approved in the US. Buprenorphine is also available in sublingual formulations with or without the opioid antagonist naloxone, in a buccal formulation with naloxone, and as a subdermal implant (Probuphine).

MAINTENANCE TREATMENT — Buprenorphine with or without naloxone is the treatment of choice for most patients with opioid use disorder. (Naloxone is added to deter intravenous or intranasal use of buprenorphine.) In patients with opioid use disorder, buprenorphine significantly improves treatment retention and reduces illicit opioid ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Once-Monthly Subcutaneous Buprenorphine (Sublocade) for Opioid Use Disorder
Article code: 1541b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian